TY - JOUR
T1 - An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
AU - Li, Danni
AU - Mielke, Michelle M.
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/12/1
Y1 - 2019/12/1
N2 - The development of blood-based biomarkers of Alzheimer’s disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential. Proteins that are reflective of AD pathology, such as amyloid beta 42 (Aβ42), tau proteins [total tau (T-tau) and phosphorylated tau (P-tau)], and neurofilament light chain (NfL), are detectable in the blood. However, a major challenge in measuring these blood-based proteins is that their concentrations are much lower in plasma or serum than in the cerebrospinal fluid. Single molecule array (SiMoA) is an ultrasensitive technology that can detect proteins in blood at sub-femtomolar concentrations (i.e., 10−16 M). In this review, we focus on the utility of SiMoA assays for the measurement of plasma or serum Aβ42, P-tau, T-tau, and NfL levels and discuss future directions.
AB - The development of blood-based biomarkers of Alzheimer’s disease (AD) pathology as tools for screening the general population, and as the first step in a multistep process to determine which non-demented individuals are at greatest risk of developing AD dementia, is essential. Proteins that are reflective of AD pathology, such as amyloid beta 42 (Aβ42), tau proteins [total tau (T-tau) and phosphorylated tau (P-tau)], and neurofilament light chain (NfL), are detectable in the blood. However, a major challenge in measuring these blood-based proteins is that their concentrations are much lower in plasma or serum than in the cerebrospinal fluid. Single molecule array (SiMoA) is an ultrasensitive technology that can detect proteins in blood at sub-femtomolar concentrations (i.e., 10−16 M). In this review, we focus on the utility of SiMoA assays for the measurement of plasma or serum Aβ42, P-tau, T-tau, and NfL levels and discuss future directions.
KW - Alzheimer’s disease
KW - Amyloid-beta
KW - Blood biomarkers
KW - Neurofilament
KW - Single molecule array technology
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=85076354986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076354986&partnerID=8YFLogxK
U2 - 10.1007/s40120-019-00164-5
DO - 10.1007/s40120-019-00164-5
M3 - Review article
C2 - 31833025
AN - SCOPUS:85076354986
SN - 2193-8253
VL - 8
SP - 73
EP - 82
JO - Neurology and Therapy
JF - Neurology and Therapy
ER -